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Abstract
Background: Transmission of drug-resistant HIV-1 (TDR) can impair the virologic response to antiretroviral combination
therapy. Aim of the study was to assess the impact of TDR on treatment success of resistance test-guided first-line therapy
in the German HIV-1 Seroconverter Cohort for patients infected with HIV between 1996 and 2010. An update of the
prevalence of TDR and trend over time was performed.
Methods: Data of 1,667 HIV-infected individuals who seroconverted between 1996 and 2010 were analysed. The WHO drug
resistance mutations list was used to identify resistance-associated HIV mutations in drug-naı̈ve patients for epidemiological
analysis. For treatment success analysis the Stanford algorithm was used to classify a subset of 323 drug-naı̈ve genotyped
patients who received a first-line cART into three resistance groups: patients without TDR, patients with TDR and fully active
cART and patients with TDR and non-fully active cART. The frequency of virologic failure 5 to 12 months after treatment
initiation was determined.
Results: Prevalence of TDR was stable at a high mean level of 11.9% (198/1,667) in the HIV-1 Seroconverter Cohort without
significant trend over time. Nucleotide reverse transcriptase inhibitor resistance was predominant (6.0%) and decreased
significantly over time (OR = 0.92, CI = 0.87–0.98, p = 0.01). Non-nucleoside reverse transcriptase inhibitor (2.4%; OR = 1.00,
CI = 0.92–1.09, p = 0.96) and protease inhibitor resistance (2.0%; OR = 0.94, CI = 0.861.03, p = 0.17) remained stable. Virologic
failure was observed in 6.5% of patients with TDR receiving fully active cART, 5,6% of patients with TDR receiving non-fully
active cART and 3.2% of patients without TDR. The difference between the three groups was not significant (p = 0.41).
Conclusion: Overall prevalence of TDR remained stable at a rather high level. No significant differences in the frequency of
virologic failure were identified during first-line cART between patients with TDR and fully-active cART, patients with TDR
and non-fully active cART and patients without TDR.
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Introduction
The wide use of combination antiretroviral therapy (cART)
succeeded in sustained inhibition of viral replication and reduced
significantly the morbidity and mortality of HIV disease [1–4].
However, treatment options can be impaired by the development
of antiretroviral drug resistance. Insufficient virus suppression
during cART is the main factor for selection of resistant HIV-1
variants. Resistant virus strains can be transmitted to new hosts
and, subsequently, can lead to antiretroviral treatment failure [5].
Loss of efficacy of cART would have extensive consequences as
the containment of disease is nearly exclusively accredited to
effective therapy. Estimates of the prevalence of transmitted drug
resistance (TDR) in Europe range from 3.3% to 14.2% [6–31]
with stable [6,20,25,26,31] or decreasing [7,10,21,24,27–30]
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trends over time. However, the increasing global use of
antiretroviral drugs may in turn increase the number of patients
at risk to select resistant viral variants under incomplete cART and
may concomitantly raise the risk of TDR.
The prevalence of people living with HIV in Germany has been
increasing continuously, and concomitantly the proportion of
patients treated with antiretrovirals has been increasing [32].
Moreover, despite the high proportion of treated HIV patients in
clinical care, current estimates show an increase in the proportion
of individuals newly infected with HIV but still undiagnosed [32].
An increase of both the use of cART and of patients recently
infected with HIV with unsuppressed viraemia raises the risk of
TDR in Germany. Hence, the surveillance of the prevalence and
time trends of TDR, resistance testing as clinical practice and
analyses of treatment success in patients with TDR receiving first-
line cART are of great importance.
Numerous studies demonstrated a significantly higher rate of
virologic failure in subjects with TDR if the antiretroviral regimen
comprised at least one drug showing reduced activity [33–36].
However, some controversial data exist regarding the impact of
TDR to treatment response if first-line treatment was resistance
test guided. At least in studies with short duration of observation a
comparable efficacy of first-line cART was observed in patients
with and without TDR if regimens comprised only active drugs
[8,15,37]. Other studies found a higher proportion of virologic
failure in the participants with TDR although they were receiving
fully active therapy [34,38]. In particular, higher odds ratio (OR)
for failure was determined if a non-nucleoside reverse transcriptase
inhibitor comprising regimen was administered [34]. In patients
from the German HIV-1 Seroconverter Study infected between
1996 and 2007 no difference was observed in response to first-line
cART between patients with and without TDR [39]. The aim of
our study was to update the analysis of prevalence and trend of
TDR in the German HIV-1 Seroconverter Cohort between 1996
and 2010 and to evaluate the impact of TDR on first-line
treatment success within the first year of treatment. In addition,




The German HIV-1 Seroconverter Study received ethical
approval first in 2005 by the ethic committee of the Charité,
University Medicine Berlin. Ethical approval was amended in
December 2012 and the amendment was confirmed by the
committee in January 2013. Patients have to sign written informed
consent. The HIV-1 Seroconverter Study is a nationwide multi-
centre open prospective cohort study which includes HIV-1-
infected individuals for whom the date of HIV-1 seroconversion is
known or reliably estimated by laboratory diagnostics. All patients
enrolled in the study signed an informed consent form. Twenty-
two clinics, forty private medical practices specialized in the care
of HIV patients and seven public health offices are involved in the
recruitment of patients. Epidemiologic, clinical and laboratory
data are collected on a yearly basis using a standardised
questionnaire. Inclusion criteria are (1) age over 18 years and (2)
an acute seroconversion confirmed by laboratory diagnostics
(acute HIV-1 seroconverters) or a documented HIV-1 serocon-
version (documented HIV-1 seroconverters) with at most a 3-year
interval between the last negative and the first confirmed positive
HIV antibody test.
Acute HIV-1 seroconverters are defined by the following
laboratory diagnostic criteria: (1) detectable HIV-1 RNA or p24
antigen combined with a negative or indeterminate ELISA result
or (2) reactive HIV-1 ELISA combined with a negative or
indeterminate immunoblot result with confirmation of complete
seroconversion within six months.
The blood sampling date of the first reactive test (acute
seroconverters) or the arithmetic mean between the last negative
and the first confirmed positive HIV antibody test (documented
seroconverter) are considered as date of infection.
Genotypic Resistance Testing
Blood samples from each individual were collected at date of
enrolment and transported to the Robert Koch Institute within 48
hours after venipuncture. 81.3% (1355/1667) of the blood samples
were taken within 365 days after calculated date of infection.
Genotypic resistance testing was performed for drug-naı̈ve
patients. The methods used have been described previously
[18,40]. In brief, the ViroSeq HIV-1 Genotyping System (Abbott,
Wiesbaden, Germany) was used to determine genotypic resistance.
Alternatively, an in-house pol RT-PCR system [41] was used to
amplify a 1.5 kb pol fragment encoding the complete protease (99
amino acids) and reverse transcriptase (1–296 amino acids).
Nucleotide sequences from drug-naı̈ve patients were processed
through the Stanford Genotypic Resistance Interpretation Algo-
rithm (HIVSeqProgram, version 6.1.1 at http://hivdb.stanford.
edu/). The identified resistance mutations were analysed by using
both the WHO surveillance drug resistance mutations list (SDRM)
[42] and the Stanford algorithm. The Stanford algorithm
comprises the mutations contained in the IAS-USA drug
resistance mutation list. The presence of at least one of the
mutations according to the SDRM list was considered as TDR for
epidemiological analysis. Resistance mutations conferring low,
intermediate and high levels of predicted resistance according to
the Stanford algorithm were considered as TDR for the analysis of
first-line cARTand clinical context. As a consequence of the use of
the Stanford algorithm HIV-1 strains encoding revertant substi-
tutions of the T215Y/F in the reverse transcriptase causing high
level resistance to thymidine analogues are included in the
treatment response analyses because they are scored with low
level resistance to AZT and D4T, and with potential level of cross
resistance to ABC, DDI and TDF. The revertants are not
contained in the IAS 2013 list of drug resistance mutations [43].
Prevalence of TDR
The prevalence of TDR was calculated as the frequency of
TDR in all drug-naı̈ve seroconverters genotyped by year of HIV-1
seroconversion (N = 1,667; 1996–2010) and by drug classes
(nucleotide reverse transcriptase inhibitors [NRTIs], non-nucleo-
side reverse transcriptase inhibitors [NNRTIs], protease inhibitors
[PIs]). To calculate the prevalence of each of the drug classes,
occurrence of drug class resistance was cumulated from mono-,
dual- and triple-resistant variants per year of seroconversion.
HIV subtype was assigned using the REGA tool [44] (REGA
HIV-1 & 2 Automated Subtyping Tool Version 2.0; http://www.
bioafrica.net/rega-genotype/html/subtypinghiv.html). In case the
REGA tool could not assign a subtype, the distance-based
neighbour joining phylogenetic tree (PHYLIP version 3.6; J.
Felsenstein) was calculated using an extended panel of subtype
reference sequences (n = 159) from the HIV sequence data base
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.
html#ref).
Analysis of Treatment Success
For analyses of the effect of TDR on treatment success, only
those patients were included (i) who were HIV-genotyped while
Treatment Response and TDR in HIV-1 Seroconverters
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drug-naı̈ve, (ii) who received a first-line cART for a minimum of
five months, (iii) whose CD4-cell count and HIV RNA viral load
(VL) were determined within 90 days before start of therapy, and
(iv) who had at least two consecutive VL measurements 5–12
months after initiation of first-line cART or until the end of first-
line cART in case first-line cART treatment duration was shorter
than 12 months (N = 323).
Patients were classified into three groups based on the
prediction of resistance by the Stanford algorithm: 1) patients
without TDR [no resistance or potential low-level resistance
mutation (Stanford level 1 and 2)], 2) patients with TDR receiving
fully active first-line cART [at least one low-level and/or
intermediate and/or high-level resistance mutation (Stanford
levels 3–5) without affecting the prescribed first-line cART], 3)
patients with TDR and non-fully active first-line cART [at least
one low-level and/or intermediate and/or high level resistance
mutation (Stanford level 3–5) affecting at least one of the
prescribed drugs of their first-line cART].
The primary outcome of this investigation was the analysis of
the frequency of virologic failure in patients without TDR, patients
with TDR receiving fully active first-line cART and patients with
TDR receiving non-fully active first-line cART. Since VLs were
determined by using various commercial kits with different
detection limits during the long observation time of the study,
VLs that remained permanently below the detection limit of 500
copies/ml were considered as treatment success. A transient
viraemia between 500–1,000 copies/ml with a subsequent drop of
VL below 500 copies/ml was considered as a blip and also assessed
as treatment success. Virologic failure was defined to be the case if
at least one of the VL measurements was above 1,000 copies/ml
or if two consecutive VLs were above 500 copies/ml.
Statistical Analysis
Descriptive statistics for continuous variables were calculated as
medians and interquartile ranges (IQR). The Mann-Whitney-U
test (MWT) and the Kruskal-Wallis test were used to compare
differences between groups. Proportions were given with a 95%-
Wilson score confidence interval (CI) based on binomial distribu-
tion. Differences in proportions were assessed by Fisher’s exact test
and chi-squared test.
For time-to-event analyses, Kaplan-Meier analyses and log rank
statistics were used in order to derive differences in duration of
first-line cART and the time interval between HIV-1 seroconver-
sion and first-line cART. Univariable and multivariable cox
proportional hazard model was performed to compare time-to-
event analyses of more than two resistance groups. For treatment
success analysis univariable and multivariable logistic regression
was used to compare differences in the frequency of virologic
failure between resistance groups. Univariable and multivariable
logistic regression models were calculated to determine predictors
of TDR such as subtype, age, sex and exposure to cART. Trend
analysis in the prevalence of TDR was performed by using
multivariable logistic regression. Multivariable models were
adjusted for sex, age and transmission group. A two-sided p-value
below 0.05 was considered significant in all statistical tests applied.
All data were analysed using STATA 10 (www.stata.com/stata10).
Figure 1. Flow chart of patient groups.
doi:10.1371/journal.pone.0095956.g001
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Results
Characteristics of the Study Population
A total of 1,727 blood samples from 1,975 HIV-1-positive
patients with known or estimated date of seroconversion were
available for analysis. Genotyping was performed in 1,695/1,727
(98.2%) of the blood samples available. 1,667 HIV-infected drug-
naı̈ve patients with a successful genotypic resistance test were
included in the analysis (figure 1). Included study participants
seroconverted between 1 January 1996 and 10 November 2010.
According to the criteria defined above, 44.8% of patients were
acute HIV-1 seroconverters and 55.2% of patients documented
HIV-1 seroconverters. At date of seroconversion, most patients
(93.5%) were classified as CDC category A. Most patients were
male (95.3%) and the median age was 33 years (IQR 27–39). The
predominant route of HIV transmission was sex between men
(MSM; 87.9%) and the dominant HIV-1 subtype was B (92.3%)
(table 1).
Prevalence of TDR in the HIV-1 Seroconverter Cohort
The overall prevalence of TDR between 1996 and 2010 (year of
seroconversion) was 11.9% (CI = 10.3–13.4;198/1667) according
to the WHO resistance mutation list (Stanford: 16,1%; CI = 14.3–
17.9; 267/1667). Neither univariable (OR = 0.99, CI = 0.99–1.00,
p = 0.06) nor multivariable trend analyses adjusted for age,
transmission group and sex showed a significant association
between date of infection and prevalence of TDR.
Transmitted NRTI resistance was identified most frequently
with 6.0% (Stanford: 5.2%) followed by NNRTI resistance with
2.4% (Stanford: 5.2%) and PI resistance 2.0% (Stanford: 2.8%).
Dual-class resistance was detected in 1.2% (Stanford: 2.7%) of
Table 1. Characteristics of study population.
Total Patients with TDR* Patients without TDR* OR (95%CI)" p-value
Genotypic resistance tested patients (%) 1,667 (100) 198 (11.9) 1,469 (88.1)
Type of seroconversion (%) 0.491
Acute 746 (44.8) 84 (42.4) 662 (45.1)
Documented 921 (55.2) 114 (57.6) 807 (54.9)
CDC category at sca (%) 0.131
A 1,544 (92.6) 181 (91.4) 1,363 (92.8)
B 94 (5.6) 16 (8.1) 78 (5.3)
C 29 (1.7) 1 (0.5) 28 (1.9)
Sex 2.06 (0.824–6.57) 0.151
Men (%) 1,588 (95.3) 193 (97.5) 1,395 (95.0)
Women (%) 78 (4.7) 5 (2.5) 73 (5.0%)
Median age at sc (IQR*) 33 (27–39) 34 (26–39) 33 (27–39) 0.872
Subtype (n = 1,664) 0.001
B subtype (%) 1,536 (92.3) 195 (99.0) 1,341 (91.4)
Non-B subtype (%) 128 (7.7) 2 (1.0) 126 (8.6)
Transmission group (%)
MSMu 1,465 (87.9) 182 (91.9) 1,283 (87.3) 1.65 (0.96–3.01) 0.061
Heterosexual contacts 110 (6.6) 8 (4) 102 (7) 0.56 (0.53–1.18) 0.161
Exposure at work 5 (0.3) 0 5 (0,3) 1.01
High prevalence country 30 (1.8) 0 30 (2) 0.041
Intravenous drug use 21 (1.2) 1 (0.5) 20 (1.4) 0.37 (0.01–2.32) 0.51
Unknown 20 (1.2) 4 (2) 16 (1.1) 1.87 (0.45–5.88) 0.291
Median VL at sc (log/ml) (IQR*) (n) 5.25 (4.5–5.9) (785) 5.2 (4.5–6.2) (82) 5.26 (4.5–5.9) (669) 0.672
Median CD4 cc, at sca (cells/ml) (IQR*) (n) 473 (350–642) (748) 528 (374–647) (79) 470 (348–641) (669) 0.482
Median duration of FL-ART6 (day) (CI) (n) 810 (571–974) (922) 477 (320–974) (122) 823 (595–1182) (800) 0.0453
Median time to FL-ART6 (day) (CI) (n) 1.011 (928–1.071) 896 (736–1.156) 1.014 (939–1.079) 0.613
Median CD4 cc, at FL-ART6 start (cells/ml) (IQR*) (n) 300.5 (213–408) (778) 303 (204–406) (102) 299.5 (214–422) (676) 0.922





uMSM: men who have sex with men].
*IQR: Interquartile range.




Treatment Response and TDR in HIV-1 Seroconverters
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e95956
patients. Triple-class resistance was only observed in 0.3%
(Stanford: 0.24%) of patients.
The prevalence of transmitted NRTI resistance according to the
SDRM list decreased strongly between 1999 and 2000 and its
overall trend was highly significant (OR = 0.92 per calendar year,
CI = 0.87–0.98, p = 0.01). Prevalence of NNRTI and PI resistance
has remained rather stable over the last years and did not show
any significant trend (NNRTI: OR = 1.00, CI = 0.92–1.09,
p = 0.96; PI: OR = 0.94, CI = 0.86–1.03, p = 0.17).
Factors Associated with TDR
The prevalence of TDR according to the SDRM list was
highest for MSM (12.4%). There were no significant differences
between patients with and without TDR regarding sex, median
age, frequency of acute or documented HIV-1 seroconversion,
CDC stage, CD4-cell count and VL at HIV-1 seroconversion. In
univariable analysis infection with HIV-1 subtype B was highly
significantly associated with TDR (OR: 9.2, CI 95%: 2.2–37.3,
p = 0.002). This factor was the only independent predictor of TDR
also in the multivariable model. Univariable and multivariable
analysis showed no association between other variables like sex,
age and route of HIV transmission and TDR.
First-line cART
First-line cART was initiated in 56.1% (936/1,667) of all
patients with successful genotypic resistance test. The median time
interval between HIV-1 seroconversion and start of first-line
cART for all patients was 1,011 days (CI 95% = 928–1,071). The
median duration of first-line cART was 810 days (CI 95% = 571–
974).
First-line cART was initiated in 55.3% (813/1,469) of patients
without TDR and in 62.1% (123/198) of patients with TDR.
Acording to the Stanford algorithm 38.2% (47/123) of treated
patients with TDR received a first-line regimen which comprised
at least one inactive drug. 19/47 patients receiving a non fully-
active regimen had a high level drug resistance (Stanford level 5).
Kaplan-Meier analysis showed a significant difference in duration
of first-line cART when comparing patients with and without
TDR (cART duration: 627 vs. 563 days, p = 0.019) (duration: 800
vs. 444 days, p = 0.048). There was no significant statistical
difference between patients with and without TDR regarding the
time interval between HIV-1 seroconversion and start of first-line
cART (1,014 vs. 896 days, p = 0.61) and CD4-cell count (299 vs.
303 cells/ml, p = 0.92) and VL at start of first-line cART (100,000
vs. 129,500 copies/ml, p = 0.5).
Patients without TDR were treated most frequently with a
regimen of 2NRTI/1NNRTI (43.3%). With similar frequency a
regimen based on 2NRTI/1PIr was used as first-line cART
(42.4%). The third most common regimen comprised an integrase
inhibitor and two NRTIs (2.8%). Within the different drug classes
the most commonly prescribed PI was lopinavir (79.7%), the most
common NNRTIs were efavirenz (65.8%) and nevirapine (33.4%).
Among NRTIs emtricitabine (64.2%) and tenofovir (65.8%) were
most commonly administered.
Patients with TDR most frequently received a 2NRTI/1PIr
containing regimen (49.6%). The combination of 2NRTI/
1NNRTI was used for 28.5% of the patients with TDR. Among
PIs lopinavir was predominantly prescribed (51.9%). Efavirenz
was favoured over nevirapine among NNRTIs (65.8% vs. 28.9%).
Emtricitabine and tenofovir were the most commonly adminis-
tered NRTIs (61.3% and 63%) (table 2 and figure 2).
Treatment Success Analysis
323 patients met the inclusion criteria for the analysis of
treatment success.
According to the Stanford algorithm there were 41 patients with
TDR receiving fully active cART, 18 patients with TDR receiving
a non-fully active cART and 264 patients without TDR receiving
cART. There were no significant differences between the three
groups regarding VL measurements at start of cART, sex, age,
transmission route and time interval between HIV-1 seroconver-
sion and start of first-line cART (table 3). The CD4-cell count of
patients with TDR and non-fully active cART was significantly
higher than in patients without TDR or patients with TDR
receiving fully active cART (322 vs. 270 vs. 272; p = 0,02).
According to the study criteria, 5.6% (3/41) of patients with
TDR and fully active cART, 5.6% (1/18) of patients with TDR
and non-fully active cART and 3.4% (9/264) of patients without
TDR experienced virologic failure within 5 to 12 months after
initiating first-line cART. The difference between the three groups
was not significant in chi-square test (0.47) and logistic regression
(TDR fully active cART vs. nonTDR: OR = 2.24, p = 0.24, TDR
non-fully active cART vs. nonTDR: OR = .67, p = 0.64). There
was also no significant difference in duration of first-line cART
between the three groups (table 3). Two of the patients without
TDR and none of the patients with TDR had transient viraemia
with a VL between 500 and 1,000 copies/ml.
Discussion
Prevalence of Transmitted Drug Resistance
For the observation period from 1996 to 2010, an overall
prevalence of 11.9% of TDR in Germany was identified in the
HIV-1 Seroconverter Study, representing a mean slightly above
the average reported from other European studies.
Comparable figures for the prevalence of TDR were reported in
cohort studies from France (10.9%) [6], Spain (12.1%) [45], Italy
(12.0%) [29], the UK (11.4% and 14.2%, respectively) [46,47] and
the Netherlands (13%) [7]. In contrast, other epidemiologic
European studies reported levels of TDR prevalence below 10%
[9,13,16,21,23,26,48].
Within the HIV-1 Seroconverter Cohort, time trends for TDR
were rather stable. The two largest surveillance studies [20,25] as
well as other European cohorts [6,26] also reported a stable
prevalence of TDR. However, a stable trend was not observed in
all European countries. Some countries report even declining
prevalence of TDR [7,10,21,24,27–30].
The high but stable level of TDR which was observed in
Germany might be influenced by different factors. In Germany the
proportion of people newly infected with HIV but yet not
diagnosed is estimated to be increasing [32], and onward
transmission of resistant HIV among newly infected patients
may occur. At the same time there is an increase in the proportion
of HIV patients receiving antiretroviral therapy [32], and
transmission of resistant HIV from treatment-experienced patients
with unsuppressed viraemia may take place. Both events might
contribute to the fact that TDR prevalence is stabilizing at a high
level in Germany.
One factor which can also impact estimates of prevalence is the
composition of the study population analysed: for HIV serocon-
verters a higher prevalence of TDR is reported than for patients
with unknown duration of infection until resistance testing is
performed [5,19]. Reversal of fitness-impairing resistant mutations
to the sensitive wild type during drug-naı̈ve course of infection
[25,49,50] may explain the lower prevalence of HIV resistance
in patients with long-standing infections. Therefore, careful
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examination of the characteristics of study populations used to
monitor TDR is required to compare the results of different
studies.
The prevalence of TDR was in addition calculated with the
Stanford algorithm to allow clinicians to put them into a clinical
context. According to the Stanford algorithm the overall
Figure 2. Composition of first-line cART 1996–2010.
doi:10.1371/journal.pone.0095956.g002
Table 2. Prescribing practices of NRTIs, NNRTIs and PIs in first-line treatment*.






















‘TDR: transmitted drug resistance according to [42].
*Drugs listed also if administered in combined pills.
doi:10.1371/journal.pone.0095956.t002
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prevalence as well as the prevalence of NNRTI resistance, PI
resistance, and dual-class resistance was higher than prevalence
rates according to the SDRM list. Since according to the SDRM
list substitutions resistance-associated positions in the viral
enzymes are not considered which are observed to be polymorphic
in some non-B subtypes (defined threshold value Bennett et al.
2009 [42]), the analysis of the predicted phenotypic resistance
according to Stanford algorithm results as expected in overall
higher prevalences of resistance in all drug classes.
Resistance against Specific Drug Classes
In concurrence with other European studies, NRTI-associated
resistance was most commonly found in the HIV-1 Seroconverter
Cohort [6,25]. The use of incomplete suppressive mono- and dual-
NRTI regimen, facilitating the selection of resistant HIV, has
declined since the early 2000s. Accordingly, a sizeable reduction in
the prevalence of NRTI resistance was observed, in particular
since the year 2000, resulting in a significant decrease in trend
analysis. The reduced use of mono- and dual-NRTI treatment
regimens, together with the lowered replication capacity of HIV
harbouring fitness-reducing resistance mutations in the viral
reverse transcriptase [51,52], has already been suggested to
contribute to the clear-cut decrease of NRTI resistance [39].
Trends in transmitted NNRTI and PI resistance were stable
over time, extending and confirming previously published data
describing the German situation [39]. In the case of PI resistance,










Patients of sample (%) 323 (100) 41 (12.7) 18 (5,6) 264 (81.7)
Sex 0.331
men (%) 311 (96.3) 38 (92,7) 18 (100) 255 (95.7)
women (%) 12 (3.7) 3 (7,3) 0 9 (4.3)
Median age at sca (IQR)* 35 (29–40) 37 (29–43) 33 (29–38) 34 (29–40) 0.43
Transmission group
MSMu (%) 292 (90.4) 34 (82.9) 16 (88.8) 242 (91.7) 0.201
Heterosexual contacts 23 (7.1) 6 (14.6) 1 (5.6) 16 (6.0) 0.131
High prevalence country 1 (0.3) 0 0 1 (0.4) 0.891
Intravenous drug use 1 (0.3) 1 (2.5) 0 0 0,031
Unknown 20 (1.2) 0 1 (5.6) 5 (1.9) 0.351
Median time to FL-ART = (day) (CI’’) 632 (559–684) 757 (557–1,014) 550 (244–800) 613 (530–666)
Univariable HR3 for time to FL-ART = (p-value) 0.87 (0.43) 1.38 (0.19) 1.00
Multivariable HR for time to FL-ART = (p-value) 0.87 (0.42) 1.44 (0.14) 1.00
Median VL6 at start of FL-ART = (log/ml) (IQR*) 5.3 (4.5–5.9) 5.23 (4.5–5.6) 4.59 (4.3–5.5) 4.95 (4.5–5.4) 0.422
Median CD4 cc, at start of FL-ART = (cells/ml)
(IQR*) (n)
277 (200–380) 270 (210–358) 350.5 (290–488) 272 (194.5–377.5) 0.022
Median duration of FL-ART = (day) (CI’’) 1,919 (1,542–*) 1,400 (916–*) 1,681 (575–2,112) 2,386 (1,542–*)
Univariable HR for duration of FL-ART = (p-value) 1.12 (0.72) 1.29 (0.52) 1.00
Multivariable HR for duration of FL-ART = (p-value) 1.16 (0.63) 1.3 (0.48) 1.00
Pat. with treatment success (2 cons. VL6
,500 copies/ml) (%)
310 (96.0) 43 (93.5) 17 (94.4) 256 (96.4)
Pat. with virologic failure (min. 1 VL6
.500 copies/ml) (%)
13 (4.0) 3 (6.5) 1 (5.6) 9 (3.4) 0.471
Univariable odds ratio to compare virological
failure (p-value)
2.24 (0.24) 1.67 (0.64) 1.00
Multivariable odds ratio to compare virological
failure (p-value)
2.34 (0.22) 1.78 (0.60) 1.00
Pat. with blip (transient VL6 ,1,000 und
.500 copies/ml) (%)




3 HR: hazard ratio.
u MSM: men who have sex with men.
‘ TDR: transmitted drug resistance according to Stanford algorithm.
* IQR: interquartile range.
‘‘ CI: 95% confidence interval.
, cc: cell count.
6VL: Viral load.
= FL-ART: first-line AR.
doi:10.1371/journal.pone.0095956.t003
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this is most likely due to a higher genetic barrier of HIV to develop
resistance to PI, in particular to ritonavir-boosted PIs. The
accumulation of several resistance mutations is necessary to induce
clinically relevant resistance [53]. In contrast to other studies,
there is no increase of transmitted NNRTI resistance, which
together with the low levels of PI resistance in newly infected
patients may reflect a low proportion of drug resistance developed
in patients under treatment and the high standard of care achieved
in Germany.
The prevalence of transmitted dual (1.2%) and triple (0.3%)
resistance was low at a total of 1.5%, which is also consistent with
findings of other European studies [19,22]. The relatively low
occurrence of transmitted multi-resistant HIV is likely to reflect
the low capacity for replication of the heavily mutated virus strains
[54]. In accordance with findings from our previous [22,39] and
other studies [22,25,26,55], subjects infected with HIV-1 subtype
B had a significantly higher risk to contract a resistant virus in the
case of a new infection in comparison to patients with HIV-1 non-
B infections. This is most likely due to the widespread use of
antiretroviral drugs in Europe and North America, especially for
patients with a HIV-1 subtype B infection.
Prescription Practice
For the majority of patients enrolled in the HIV-1 Seroconver-
ter Cohort the prescription practice is in line with current
international treatment guidelines which recommend that patients
without TDR should receive two NRTIs and one NNRTI, or
alternatively a boosted PI [56,57]. Furthermore, prescription
practices for individual drugs were related to treatment guidelines
in most of the cases [57–59].
Therapeutic Success
In our study there was no significant difference in the frequency
of virologic failure between patients with and without TDR. he
baseline parameters were comparable for both groups [60].
A sensitivity analysis was performed to compare the subpopu-
lation that was included to assess therapeutic success with the
patients of the cohort not included in analysis. The analysis
revealed that the CD4-cell count/of patients included in the
subpopulation was significantly lower than in excluded patients,
both at the date of HIV-1 seroconversion and at the beginning of
first-line cART277 vs. 329). Furthermore – and in line with
previous findings – the time span between HIV-1 seroconversion
and commencement of first-line cART was significantly shorter in
the subpopulation (627 vs. 1,220 days). At the same time, the
duration of first-line therapy was significantly higher in the
subpopulation (1,954 vs. 244 days). This may be due to the fact
that the inclusion criteria for selecting the subpopulation reduced
the censoring for loss to follow up in the sample. It is possible that
the low CD4-cell count at base line among the patients of the
subpopulation triggered a more thorough monitoring of these
patients, which in turn generated sufficient data to include them in
the treatment response analysis in the first place. A number of
studies could show that, at least over a shorter observational
period, therapeutic effects for patients with TDR were comparable
to those of patients without TDR when treated with a fully active
regimen [8,15,37,55]. However, these observations have been
challenged, as some available data suggests that patients with TDR
achieve worse levels of viral suppression throughout first-line
cART, even when the drug regime is adjusted for existing
resistance [34,38]. According to the same study, it also took
patients with TDR significantly longer to achieve viral suppres-
sion.
A possible cause for treatment failure despite adequate
antiretroviral therapy is discussed for the presence of drug-
resistant minor variants in the infected individual. Such resistant
minorities are not detected by standard resistance testing based on
population sequencing which was used in this study. Resistant viral
strains in the viral quasispecies are only detected by population
sequencing if they occur at least at a proportion of approximately
25% in the viral quasispecies. Mutations with very low prevalence
down to 0.1% can be detected with ultrasensitive sequencing
methods (ultra-deep sequencing); however, these tests are not
routinely applied in resistance testing [61]. When these minorities
were taken into account the estimated prevalence of TDR was
clearly higher [55,62–65], usually twice as high [55,62,63]. The
clinical impact of such resistant minorities has not yet been
conclusively established.
A number of studies have shown that treatment-relevant minor
mutations led to a significant increase in therapeutic failure,
especially in the case of NNRTI-containing regimen [61–
63,66,67]. Other studies, however, did not report any effect of
resistant minorities on either therapeutic success [55,64] or
immunologic parameters [64]. undetected minor resistant viral
strains might have also contributed to virologic failure in groups.
Use of Genotypic Resistance Test Results among Whole
Study Population
The duration of first-line cART for all patients with TDR (198/
1,667) included in the study was significantly shorter than it was
for patients without TDR. Of the 123 patients with TDR, who
also commenced first-line ART, 38.2% were not treated
appropriately despite genotypic resistance results. One possible
reason for the difference in duration of first-line treatment may
thus be changes of the initial cART regime, if the latter proved
inefficient.
There are numerous reasons for the high proportion of
therapeutic regimes of the study population that were inappropri-
ate in light of existing drug resistance. For more than half of the
patients of the study population, treatment was initiated after
2004, which means that the lack of standardised testing for
resistance which was true for the late 1990s and early 2000s
cannot account for all of the observed results. Furthermore, a
physician’s decision about the appropriate way to treat a resistant
infection might not only focus on effectiveness but may also be
influenced by the management of side effects and appropriate
dosage of drugs. This may result in a compromise in that a not
fully potent therapy is implicitly accepted.
Limitations
Similar to other cohort studies with target populations of acute
HIV-1 seroconverters, the proportion of male patients with a
homosexual transmission risk is very high. Compared to German
national HIV-registration data the proportion of MSM in the
HIV-1 Seroconverter Study is clearly higher (51.3% vs. 87.9%).
For this transmission group, which accounts for the largest share of
HIV-infected patients in Germany [32], the data is representative.
Conversely, a selection bias towards patients who get tested for
HIV more frequently cannot be ruled out. Consequently, the
results reported in this paper may not be representative for other
demographic parameters and geographic regions.
A further limitation of this study is the need to define the
threshold for the detection of VL at 500 copies/ml because of the
long study period from 1996 to 2010, even though current VL
assays are much more sensitive. It should be also noted, that the
HIV-1 Seroconverter Study is an observational study. The lack of
systematic recordings of data which are mandatory for the
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enrolment of patients in the treatment success analysis as well as
data regarding changes of medication and compliance of patients
makes it difficult to increase the sample size and establish causal
relationships for observed differences within the cohort.
With regard to prevalence estimates of TDR, an underestima-
tion of the real proportion cannot be ruled out. First, there was no
testing for resistant minorities. Secondly, for documented HIV-1
seroconverters a period of three years could pass between the last
negative and first positive HIV test. Because of this, reversions
from resistant viruses to the sensitive wild type and, consequently,
a reduction in the number of detectable mutations may have
occurred. However, for 72.4% of the study population, the time
span between both tests was less than a year, which distinctly limits
the impact of potential reversions on the reported findings.
In conclusion, the prevalence of TDR within the HIV-1
Seroconverter Cohort was high at an overall level of 11.9% (1996–
2010) and stable over time, which is consistent with findings of
other European studies. The persistence of TDR in this and in
other cohorts, as well as the increasing global migration of HIV-
infected persons, underline the need for a comprehensive
surveillance system for TDR in Germany.
For the majority of patients, the administered cART met
current standards and complied with national and international
treatment guidelines. Nevertheless, according to our findings,
38.2% of patients with TDR did not receive treatment that was
adjusted for existing HIV resistances, which might explain the
significant difference in the duration of treatment between patients
with and without TDR.
Future investigations are needed to identify HIV minorities in
plasma samples in order to analyse differences in outcome of first-
line ART more deeply.
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